Tag: shockwave medical

In this issue: Paclitaxel-coated devices: US FDA removes red flag after review finds data do not support mortality risk “A hugely exciting time”: Experts...

NOTE: This video is ONLY available to watch in selected countries and geographies  The benefits of Shockwave Medical’s new Shockwave L6 Peripheral Intravascular Lithotripsy (IVL)...

NOTE: This video is ONLY available to watch in selected countries and geographies Experts gathered at the Society for Vascular Surgery’s 2023 Vascular Annual...

This advertorial is sponsored by Shockwave Medical. Mazin Foteh, MD, contrasts the benefits of Shockwave Medical’s new Shockwave L6 Peripheral Intravascular Lithotripsy Catheter alongside those...

The US launch of a new peripheral intravascular lithotripsy (IVL) catheter, new data on large bore mechanical thrombectomy in high-risk pulmonary embolism (PE) patients,...

Shockwave Medical today announced the full US commercial availability of the Shockwave L6 peripheral intravascular lithotripsy (IVL) catheter following clearance by the US Food...

 As the new kid on the block, endovascular treatment of the common femoral artery (CFA) just does not have that long-term outcome data yet,”...

 Giacomo Isernia (Perugia, Italy) sits down with Vascular News to discuss the challenges posed by calcium when it comes to endograft delivery. Calcium “limits the ability...

Treatment of common femoral artery (CFA) stenosis, either with an open or endovascular approach, is the subject of much debate, Raphaël Coscas (Paris, France)...

 Bella Huasen (Preston, UK) talks to Vascular News about some of the difficulties of treating occlusive disease in the femoropopliteal segment and why it is “essential...

This article forms part of an educational supplement sponsored by Shockwave Medical. Explore the full Compliance is Key series here. Raphaël Coscas (Ambroise Paré Hospital, AP-HP...

This article forms part of an educational supplement sponsored by Shockwave Medical. Explore the full Compliance is Key series here. Giacomo Isernia and Gioele Simonte...

This article forms part of an educational supplement sponsored by Shockwave Medical. Explore the full Compliance is Key series here. In this case report, Narayanan...

This article forms part of an educational supplement sponsored by Shockwave Medical. Explore the full Compliance is Key series here. Bella Huasen (Lancashire Teaching Hospitals...

This article forms part of an educational supplement sponsored by Shockwave Medical. Explore the full Compliance is Key series here. Stefano Fazzini (Tor Vergata Hospital,...

This educational supplement is sponsored by Shockwave Medical. Explore the full Compliance is Key series here. In this supplement: Stefano Fazzini (Tor Vergata Hospital, Rome,...

November's top 10 includes the first results from BEST-CLI, as well as new data presented at this year's Vascular Interventional Advances (VIVA; 31 October–3...

The final 1,373-patient cohort analysis from the Disrupt PAD III observational study (OS) demonstrates consistent intravascular lithotripsy (IVL; Shockwave Medical) outcomes in complex and...

 Intravascular Lithotripsy (IVL; Shockwave Medical) gives physicians “the option to treat a patient efficiently without implanting something like a stent, which would limit further...

 Raphaël Coscas (Paris, France) talks to Vascular News about his introduction to Intravascular Lithotripsy (IVL; Shockwave Medical) and his initial experiences with the technology in...

Two-year data on the use of intravascular lithotripsy (IVL) in calcified peripheral disease treatment, an advertorial sponsored by Bentley exploring the role of bridging...

Shockwave Medical and Genesis MedTech Group announced today that they have successfully obtained approval from China’s National Medical Products Administration (NMPA) to market and...

Shockwave Medical announced today that long-term data from the Disrupt PAD III trial found that superior vessel preparation with intravascular lithotripsy (IVL) led to...

This educational supplement is only available in selected countries and geographies. In this supplement, sponsored by Shockwave Medical: Marianne Brodmann (Medical University of...

Shockwave Medical has announced the global commercial availability of the Shockwave M5+ peripheral intravascular lithotripsy (IVL) catheter after receiving both CE mark and US...

November's top 10 features a large-scale analysis of Philips' intravascular ultrasound (IVUS) in lower extremity peripheral vascular interventions, five-year data on Avenu Medical/Medtronic's Ellipsys...

Shockwave Medical has announced the start of the Disrupt BTK II postmarket study to assess the safety, effectiveness and optimal clinical use of the...

Shockwave Medical has announced that, as part of the calendar year 2022 Medicare Hospital Outpatient Prospective Payment System (OPPS) final rule, the Centers for...

An interim analysis from the DISRUPT PAD III observational study showed that intravascular lithotripsy (IVL; Shockwave Medical) performs “consistently well” across challenging peripheral vessels,...

Shockwave Medical has announced that as part of the calendar year 2021 Medicare Hospital Outpatient Prospective Payment System (OPPS) final rule, the Centers for...

In this supplement, sponsored by Shockwave: Frank Arko discusses his experience with intravascular lithotripsy (IVL) and considers its value in a resource-constrained healthcare environment ...

Shockwave Medical announced today that the Centers for Medicare & Medicaid Services (CMS) has issued new codes for intravascular lithotripsy (IVL) procedures performed in...

George Adams (Raleigh, USA) talks to VEITHtv at the VEITHsymposium 2019 (19–23 November, New York, USA) about the benefits of using easy-to-use Shockwave IVL (Intravascular Lithotripsy) in calcified...

 Frank Arko (Charlotte, USA) talks to VEITHtv at the VEITHsymposium 2019 (19–23 November, New York, USA), about the benefits of using Shockwave Intravascular Lithotripsy (IVL) when performing EVAR...

Shockwave Medical today announced commercial availability of the Shockwave S4 peripheral intravascular lithotripsy (IVL) catheter in select approved geographies. Shockwave S4 is a low-profile...

Andrew Holden (Auckland, New Zealand) provides perspective on the first results from the Disrupt PAD III observational registry that were presented at the Charing...

Abiomed is to invest US$15 million in Shockwave Medical and the two companies will collaborate on a training and education programme in the USA...

 Treating severely calcified arteries by endovascular means is still a challenge, although atherectomy, stents and lithotripsy are all techniques that are employed. Lithotripsy (also...

Twelve-month data prove that intravascular lithotripsy; a novel approach using pulsatile sonic pressure waves to modify intimal and medium calcium in stenotic peripheral arteries,...

In an exciting session at the Charing Cross Symposium (CX; 24-27 April, London, UK), the audience witnessed the demonstration of a novel treatment strategy...

Shockwave Medical has reported US$35 million in new financing, an extension of the company’s previously announced US$45 million Series C financing. New investor Fidelity Management...

Shockwave Medical has reported positive results from the DISRUPT BTK Study, which were presented at the annual Cardiovascular and Interventional Radiological Society of Europe...

Shockwave Medical has announced two milestones for its Lithoplasty system for the treatment of calcified plaque in patients with peripheral artery disease (PAD): enrolment...

Shockwave Medical has announced the appointment of Doug Godshall as president and chief executive officer. Godshall was most recently the chief executive officer and a...

PinnacleHealth CardioVascular Institute has enrolled the first US patient in a trial assessing the safety and effectiveness of a new type of approach for...

Shockwave Medical has announced the closing of US$45 million in Series C financing led by Sectoral Asset Management, with participation from mutual funds advised...

Shockwave Medical has announced plans for DISRUPT PAD III—what is claims is the “largest ever” multicentre randomised study to exclusively enrol patients with calcified...

Shockwave Medical has announced positive clinical results from the pooled DISRUPT PAD Study, a single-arm, two-phase, multicentre study evaluating the safety and performance of...

Shockwave Medica has announced clearance from the US Food and Drug Administration (FDA) of the Lithoplasty system for the treatment of calcified plaque in...

Lithoplasty is a novel balloon-based technology that utilises integrated lithotripsy, a pulsatile mechanical energy commonly used to break up kidney stones, to disrupt both superficial and deep calcium and normalise vessel wall compliance prior to low-pressure balloon dilatation.